{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:10:51Z","timestamp":1791616251546,"version":"4.3.4"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody-drug conjugates (ADCs) are a fast-growing class of cancer drugs designed to selectively deliver cytotoxic payloads through antibody binding to cancer cells with high expression of the target antigen, thus reducing systemic exposure and minimizing off-target effects. However, ADCs are associated with various ocular adverse events (AEs) that may impact treatment administration and patient outcomes. In this review, we provide a summary of ocular AEs associated with approved and investigational ADCs, recommendations for the mitigation and management of ocular AEs, current guidelines and expert opinions, and recommendations for clinical practice. A literature search was performed, using PubMed and Google Scholar, for English-language articles published between January 1985 and January 2023 to identify studies reporting ocular AEs associated with ADC use. Search terms included generic and investigational names of all identified ADCs, and further searches were performed to identify strategies for managing ADC-associated ocular AEs. ADC-associated ocular AEs include symptoms such as blurred vision and foreign-body sensation and signs such as corneal fluorescein staining, corneal pseudomicrocysts, and conjunctivitis. Reported management strategies include ADC dose modification (eg, dose delay or reduction), cool compresses, artificial tears, topical vasoconstrictors, and topical steroids. Although ADC dose modification appears to be beneficial, the preventive and\/or therapeutic benefits of the remaining interventions are unclear. Although the exact mechanisms are not fully understood, most ADC-associated ocular AEs are reversible with dose delay or dose reduction. Management of ocular AEs requires a multidisciplinary approach to minimize treatment discontinuation and optimize clinical outcomes.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae177","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T16:55:37Z","timestamp":1720716937000},"page":"e1435-e1451","source":"Crossref","is-referenced-by-count":38,"title":["Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5061-0072","authenticated-orcid":false,"given":"Grace K","family":"Dy","sequence":"first","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY 14203 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim V","family":"Farooq","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, University of Chicago Medical Center , Chicago, IL 60612 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann J","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Montefiore Medical Center, Albert Einstein College of Medicine , Bronx, NY 10461 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"10200","key":"2024110817092629700_CIT0001","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"2024110817092629700_CIT0002","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024110817092629700_CIT0003","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"issue":"20","key":"2024110817092629700_CIT0004","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"2024110817092629700_CIT0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"2024110817092629700_CIT0006","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.3390\/ijms21155510","article-title":"Antibody-drug conjugates: the new frontier of chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024110817092629700_CIT0007","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2021.11.016","article-title":"Antibody drug conjugates in non-small cell lung cancer: an emerging therapeutic approach","volume":"163","author":"Marks","year":"2022","journal-title":"Lung Cancer"},{"issue":"1","key":"2024110817092629700_CIT0008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/antib2010113","article-title":"Antibody drug conjugates as cancer therapeutics","volume":"2","author":"Trail","year":"2013","journal-title":"Antibodies"},{"key":"2024110817092629700_CIT0009","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"7","key":"2024110817092629700_CIT0010","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"2024110817092629700_CIT0011","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"2024110817092629700_CIT0012","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"11","key":"2024110817092629700_CIT0013","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1007\/s12094-023-03261-y","article-title":"Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy","volume":"25","author":"Dom\u00ednguez-Llamas","year":"2023","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"2024110817092629700_CIT0014","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"key":"2024110817092629700_CIT0015","author":"U.S. Department of Health and Human Services","year":"2017"},{"issue":"12","key":"2024110817092629700_CIT0016","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024110817092629700_CIT0017","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024110817092629700_CIT0018","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"2024110817092629700_CIT0019","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/10428194.2021.1978090","article-title":"Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate","volume":"63","author":"Costa","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2024110817092629700_CIT0020","first-page":"Doc29","article-title":"Brentuximab vedotin related bilateral Purtscher-like retinopathy unresponsive to pulse steroid therapy and intravitreal aflibercept injection","volume":"7","author":"Ayhan","year":"2017","journal-title":"GMS Ophthalmol Cases"},{"key":"2024110817092629700_CIT0021","doi-asserted-by":"crossref","first-page":"101440","DOI":"10.1016\/j.ajoc.2022.101440","article-title":"Brentuximab vedotin induced uveitis","volume":"26","author":"Therssen","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"29","key":"2024110817092629700_CIT0022","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"2024110817092629700_CIT0023","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2024110817092629700_CIT0024","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"issue":"13","key":"2024110817092629700_CIT0025","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"2024110817092629700_CIT0026","doi-asserted-by":"crossref","first-page":"LBA5507","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507","article-title":"Phase III MIRASOL (GOG 3045\/ENGOT-ov55) study: initial report of mirvetuximab soravtansine vs. investigator\u2019s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression","volume":"41","author":"Moore","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024110817092629700_CIT0027","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024110817092629700_CIT0028","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1111\/cas.15443","article-title":"Tisotumab vedotin in Japanese patients with recurrent\/metastatic cervical cancer: results from the innovaTV 206 study","volume":"113","author":"Yonemori","year":"2022","journal-title":"Cancer Sci"},{"issue":"5","key":"2024110817092629700_CIT0029","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024110817092629700_CIT0030","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"2024110817092629700_CIT0031","year":"2022"},{"issue":"12","key":"2024110817092629700_CIT0032","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2024110817092629700_CIT0033","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2024110817092629700_CIT0034","year":"2022"},{"issue":"19","key":"2024110817092629700_CIT0035","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2024110817092629700_CIT0036","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"2024110817092629700_CIT0037","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024110817092629700_CIT0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ijgc-2022-003927","article-title":"Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study","volume":"33","author":"Santin","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"16_suppl","key":"2024110817092629700_CIT0039","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1200\/JCO.2022.40.16_suppl.4136","article-title":"Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208","volume":"40","author":"Spiliopoulou","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"2024110817092629700_CIT0040","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-22-0456","article-title":"Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024110817092629700_CIT0041","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.13992","article-title":"A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"173","author":"Coiffier","year":"2016","journal-title":"Br J Haematol"},{"issue":"8","key":"2024110817092629700_CIT0042","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","article-title":"A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy","volume":"103","author":"Trn\u0115n\u00fd","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"2024110817092629700_CIT0043","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clml.2015.12.004","article-title":"A phase II study of coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4 suppl","key":"2024110817092629700_CIT0044","doi-asserted-by":"crossref","first-page":"GS1-05","DOI":"10.1158\/1538-7445.SABCS21-GS1-05","article-title":"Datopotamab deruxtecan in advanced\/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study","volume":"82","author":"Krop","year":"2022","journal-title":"Cancer Res"},{"key":"2024110817092629700_CIT0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9004","article-title":"TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC)","author":"Goto","year":"2023"},{"key":"2024110817092629700_CIT0046","article-title":"Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced\/metastatic (adv\/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01","author":"Ahn","year":"2023"},{"issue":"10","key":"2024110817092629700_CIT0047","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-21-3656","article-title":"Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase I\/II trial","volume":"28","author":"Boni","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5 suppl","key":"2024110817092629700_CIT0048","doi-asserted-by":"crossref","first-page":"P4-01-15","DOI":"10.1158\/1538-7445.SABCS22-P4-01-15","article-title":"Abstract P4-01-15: preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)","volume":"83","author":"Miller","year":"2023","journal-title":"Cancer Res"},{"issue":"8","key":"2024110817092629700_CIT0049","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"2024110817092629700_CIT0050","doi-asserted-by":"crossref","first-page":"S1288","DOI":"10.1016\/j.annonc.2021.08.2088","article-title":"LBA15 primary outcome of the phase III SYD985.002\/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician\u2019s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer","volume":"32","author":"Saura Manich","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"2024110817092629700_CIT0051","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann Oncol"},{"key":"2024110817092629700_CIT0052","doi-asserted-by":"crossref","article-title":"Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen related cell adhesion molecule 5 (CEACAM5)","author":"Gazzah","DOI":"10.1200\/JCO.2020.38.15_suppl.9505"},{"issue":"16_suppl","key":"2024110817092629700_CIT0053","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1200\/JCO.2022.40.16_suppl.9039","article-title":"Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)","volume":"40","author":"Ricordel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2024110817092629700_CIT0054","doi-asserted-by":"crossref","first-page":"e15003","DOI":"10.1200\/JCO.2023.41.16_suppl.e15003","article-title":"Phase 1\/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events","volume":"41","author":"Gazzah","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024110817092629700_CIT0055","year":"2022"},{"issue":"10","key":"2024110817092629700_CIT0056","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024110817092629700_CIT0057","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2024110817092629700_CIT0058","author":"European Medicines Agency","year":"2022"},{"key":"2024110817092629700_CIT0059","year":"2022"},{"key":"2024110817092629700_CIT0060","volume-title":"GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation","year":"2022"},{"issue":"2","key":"2024110817092629700_CIT0061","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro Oncol"},{"key":"2024110817092629700_CIT0062","author":"European Medicines Agency","year":"2022"},{"key":"2024110817092629700_CIT0063","author":"European Medicines Agency","year":"2022"},{"key":"2024110817092629700_CIT0064","year":"2023"},{"key":"2024110817092629700_CIT0065","year":"2023"},{"issue":"21","key":"2024110817092629700_CIT0066","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/1078-0432.CCR-20-1067","article-title":"A phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024110817092629700_CIT0067","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2021.09.023","article-title":"An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer","volume":"163","author":"Liu","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2024110817092629700_CIT0068","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1078-0432.CCR-18-3965","article-title":"Phase Ia study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin DNIB0600A in patients with non-small cell lung cancer and platinum-resistant ovarian cancer","volume":"26","author":"Gerber","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024110817092629700_CIT0069","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2020.05.039","article-title":"Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer","volume":"158","author":"Moore","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"Suppl 1","key":"2024110817092629700_CIT0070","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S0959-8049(22)01043-7","article-title":"A phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage","volume":"174","author":"Ulahannan","year":"2022","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"2024110817092629700_CIT0071","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/S0090-8258(22)01523-2","article-title":"A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301)","volume":"166","author":"Tolcher","year":"2022","journal-title":"Gynecol Oncol"},{"key":"2024110817092629700_CIT0072","volume-title":"Exelixis announces promising initial dose-escalation results from the first-in-human phase 1 JEWEL-101 trial evaluating XB002 in patients with advanced solid tumors at ENA 2022","year":"2022"},{"issue":"3","key":"2024110817092629700_CIT0073","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"2024110817092629700_CIT0074","author":"European Medicines Agency","year":"2022"},{"issue":"15_suppl","key":"2024110817092629700_CIT0075","doi-asserted-by":"crossref","first-page":"9058","DOI":"10.1200\/JCO.2021.39.15_suppl.9058","article-title":"TROPION-PanTumor01: dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract]","volume":"39","author":"Meric-Bernstam","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2024110817092629700_CIT0076","doi-asserted-by":"crossref","first-page":"TPS9127","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9127","article-title":"A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01)","volume":"39","author":"Yoh","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024110817092629700_CIT0077","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target","volume":"59","author":"Stepan","year":"2011","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"2024110817092629700_CIT0078","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2024110817092629700_CIT0079","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"2024110817092629700_CIT0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024110817092629700_CIT0081","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2024110817092629700_CIT0082","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1755-3768.2012.02518.x","article-title":"The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists","volume":"91","author":"Ho","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"2024110817092629700_CIT0083","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","article-title":"Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial","volume":"105","author":"Popat","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2024110817092629700_CIT0084","doi-asserted-by":"crossref","first-page":"P94","DOI":"10.1016\/j.ophtha.2018.10.020","article-title":"Conjunctivitis Preferred Practice Pattern\u00ae","volume":"126","author":"Varu","year":"2019","journal-title":"Ophthalmology"},{"issue":"12","key":"2024110817092629700_CIT0085","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1002\/ajh.26728","article-title":"Corneal toxicity with belantamab mafodotin: multi-institutional real-life experience","volume":"97","author":"Mohan","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2024110817092629700_CIT0086","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.18298","article-title":"Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma","volume":"199","author":"Abeykoon","year":"2022","journal-title":"Br J Haematol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1435\/60541874\/oyae177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1435\/60541874\/oyae177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T12:10:00Z","timestamp":1731067800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/11\/e1435\/7719341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":86,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae177","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,24]]}}}